# EDGAR Filing Document

**Accession Number:** 0002019505
**File Stem:** 0001213900-25-108537
**Filing Date:** 2025-11
**Character Count:** 25347
**Document Hash:** db5139052dcafaf6d59e06b715e3fd79
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-108537.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001213900-25-108537

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251110

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Health In Tech, Inc.
- **CENTRAL INDEX KEY:** 0002019505
- **STANDARD INDUSTRIAL CLASSIFICATION:** INSURANCE AGENTS BROKERS & SERVICES [6411]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42449
- **FILM NUMBER:** 251468435

**BUSINESS ADDRESS:**
- **STREET 1:** 701 S. COLORADO AVE
- **STREET 2:** SUITE 1
- **CITY:** STUART
- **STATE:** FL
- **ZIP:** 34994
- **BUSINESS PHONE:** 888-373-0333

**MAIL ADDRESS:**
- **STREET 1:** 701 S. COLORADO AVE
- **STREET 2:** SUITE 1
- **CITY:** STUART
- **STATE:** FL
- **ZIP:** 34994

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**November 10, 2025**

Date of Report (Date of earliest event reported)

**<u>Health In Tech, Inc.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-42449** | **87-3545722** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **701 S. Colorado Ave, Suite 1**<br> **Stuart, FL** | **34994** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(888) 373-0333**

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Class A Common Stock, $0.001 par value per share | HIT | The Nasdaq Stock Market LLC<br> (Nasdaq Capital Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01. Regulation FD Disclosure.**

*Earnings Call Script*

On November 10, 2025, Health In Tech, Inc., a Nevada corporation (the "Company") hosted a conference call to discuss its financial and operating results for the quarter ended September 30, 2025. A transcript of the conference call is furnished as Exhibit 99.1 to this Current Report on Form 8-K. As previously disclosed, a replay of the entire conference call is available for on-demand listening through approximately February 8, 2026 via the Investor Relations page of the Company's website at https://healthintech.investorroom.com/Events?item=17.

The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 are deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

*Forward-Looking Statements*

Certain statements in this Current Report on Form 8-K are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech's possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "design," "target," "aim," "hope," "expect," "could," "intend," "plan," "anticipate," "estimate," "believe," "continue," "predict," "project," "potential," "goal," or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech's actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause the Company's actual results to differ materially from those presented in its forward-looking statements are set forth in the "Risk Factors" section in the Company's Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in the Company's subsequent reports. Any forward-looking statement reflects Health In Tech's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech's operations, results of operations, growth strategy and liquidity.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Transcript.](ea026513201ex99-1_health.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 12, 2025

HEALTH IN TECH, INC.

---

| | |
|:---|:---|
| By: | */s/ Tim Johnson* |
| Name: | Tim Johnson |
| Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

Q3 2025 Earnings Conference Call

*November 10, 2025*

 

*5:00 PM EST (New York)*

**Presenter Dial-In Number:**

Presenter Dial-In (Toll Free): 1-866-250-8117

Presenter International Dial-In: 1-412-317-6011

Presenters are asked to please connect a minimum of 15 minutes prior to the conference start time. When the speakers are connected, the conference specialist will do a brief sound check for your line. You will also be asked to review the following items: verify conference title, the first speaker's name and pronunciations of other speakers' names, Q&A restrictions or priority questioners, who will read the safe harbor language, any questions regarding special services or requests.

Link to View Q&A:

https://qa6.choruscall.com/contexweb/ViewQA/loginSortQA.htm

View Q&A Conference Code: 10204413

**Operator**

Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Health In Tech third quarter of 2025 earnings conference call. Currently, all participants are in listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, we are recording today's call. If you have any objections, you may disconnect at this time.

Now I will turn the call over to Lori Babcock, Chief of Staff for the company, Ms. Babcock, please proceed.

**Lori Babcock – Chief of Staff**

Thank you, operator, and hello, everyone. Welcome to the Health in Tech's third quarter of 2025 earnings conference call, joining us today are Mr. Tim Johnson, Chief Executive Officer, Mr. Dustin Plantholt, Chief AI & Marketing Officer, and Ms. Julia Qian, Chief Financial Officer. Full details of our results can be found in our earnings press release and in our related Form 10-Q, to be filed with the SEC. These documents will be available on our Investor Relations website at healthintech.investorroom.com. As a reminder, today's call is being recorded, and a replay will be available on our IR website as well.

Before we continue, please note that today's discussion includes forward-looking statements made pursuant to the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on information available as of today and involve risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied, including those discussed in our quarterly report on Form 10-Q for the period ended September 30, 2025, to be filed with the SEC. Please review the forward-looking and cautionary statements section at the end of our earnings release for various factors that could cause actual results to differ materially from forward-looking statements made during our call today.

We undertake no obligation to update and expressly disclaim the obligation to update these forward-looking statements to reflect events or circumstances after the date of this call or to reflect new information or the occurrence of unanticipated events. We may also refer to certain financial measures not in accordance with generally accepted accounting principles, such as adjusted EBITDA for comparison purpose only. Our GAAP results and reconciliations of GAAP to non-GAAP measures can be found in our earnings press release.

With that, I will now turn the call over to our CEO, Mr. Tim Johnson.

![](ex99-1_001.jpg)

**Tim Johnson – CEO**

Thank you, and good afternoon, everyone. I appreciate you joining us today.

I'm pleased to share our third quarter results, which were well aligned with our expectations as we continued to invest in strategic channel partners and rapidly expand our distribution network.

At a high level, we delivered another quarter of strong revenue growth. Revenue reached $8.5 million, up 90% year over year, bringing nine-month revenue to $25.8 million, compared to $19.5 million for the full year 2024.

This momentum was driven by the continued expansion of our sales distribution network. The number of brokers, TPAs, and agencies grew to 849 partners, up 57% year over year. As more brokers and agencies adopt our eDIYBS platform, we're seeing more quotes bound and sold in real time. By the end of the third quarter, the number of billed enrolled employees reached 25,248, an increase of 7,654 employees year over year.

The third quarter is typically a development and deployment period for us—a time to introduce new programs and features.

Most notably, we completed beta testing and officially launched the large-employer underwriting capability within our enhanced eDIYBS platform.

This is a major milestone that scales our reach across the full employer spectrum, positioning Health In Tech as a true insurance marketplace for businesses of all sizes. The new capability enables brokers to generate fully bindable quotes for groups of 150 or more employees in as little as two weeks, compared to the industry norm of about three months. This advancement dramatically expands our addressable market and establishes Health In Tech among the few platforms serving both small and large employers seamlessly.

Soon after the launch, we showcased this innovation at the SIIA National Conference in October 2025, one of the most influential events in the self-insurance industry. Our participation there helped accelerate national exposure and strengthen broker relationships—key catalysts for future growth.

As we look to the fourth quarter and into Q1 2026, we're entering our peak enrollment period when employers review or switch their healthcare coverage. Recent market uncertainty and rising healthcare costs have created mixed timing patterns — with some employers making early plan selections in late Q3, while others are delaying decisions into January. As a result, we delivered much better year over year growth in Q3, and anticipating sales volume shift from Q4 into Q1, but still expect healthy year-over-year growth overall.

To help employers navigate cost volatility, we're testing a new program offering a three-year rate hold—a solution that provides predictable, stable pricing over a multi-year period.The program allows groups with 150 or more employees to lock in healthcare costs for three years through a fixed remittance model backed by an A-rated stop-loss carrier.

It brings real value to clients looking for cost stability amid rising medical expenses, while also strengthening our relationships with brokers and TPAs. By providing cost certainty amid rising medical expenses, we're giving brokers and TPAs a powerful retention tool and helping employers plan long term with greater confidence. We completed initial testing in October and plan to fully launch the program in the first quarter of 2026.

We believe it represents an innovative concept for the broader healthcare insurance market and we're optimistic about its reception as we enter 2026.

Beyond underwriting innovation, we're setting our sights on one of the largest inefficiencies in U.S. healthcare—claims processing, which consumes more than $300 billion annually in administrative costs and delays.

![](ex99-1_001.jpg)

This quarter, we announced a non-binding Letter of Intent with AlphaTON Capital Corp. to co-develop HITChain, a blockchain-enabled platform designed to bring real-time visibility, accuracy, and accountability to claims workflows across the ecosystem.

Under this LOI, both companies plan to contribute distinct strengths:

Health In Tech brings domain expertise in insurance and healthcare data standards, established broker and carrier relationships, proven go-to-market channels, and leadership in health technology design.

AlphaTON Capital contributes blockchain development expertise on The Open Network (TON), smart contract architecture, cybersecurity, stablecoin integration for secure payments, and capital resources for enterprise-scale deployment.

Together—with AlphaTON's blockchain infrastructure and Brittany Kaiser's leadership in data ethics—we are building HITChain, a decentralized and verifiable claims system aimed at compressing timelines, eliminating duplication, reducing costs, and creating a transparent system of record for payers and providers alike.

By combining insurance domain expertise with blockchain innovation, Health In Tech is positioned at the forefront of decentralized healthcare insurance technology infrastructure—a market opportunity of meaningful scale and long-term impact.

Lastly, we're thrilled to share that Health In Tech will host the InsurTech Summit in Davos during the World Economic Forum week in January 2026. This event will convene global thought leaders to discuss AI, technology, and the transformation of critical business sectors, including healthcare and insurance.

With that, I'll now turn it over to Dustin, who will walk through our latest marketing and partnership initiatives in greater detail.

**Dustin Plantholt– Chief AI & Marketing Officer**

Thank you, Tim, and good afternoon, everyone.

As Tim mentioned, we will take Health In Tech to the center of the global innovation stage by hosting our first Independent InsurTech Summit on January 20, 2026, during the World Economic Forum Week in Davos, Switzerland.

The World Economic Forum, held each January in Davos, is one of the world's most prestigious gatherings of global leaders across business, government, academia, and civil society. It serves as a powerful platform for shaping global, regional, and industry agendas—and this year, Health In Tech will be among the organizations leading that dialogue.

Our Summit will feature a curated lineup of panels on artificial intelligence, digital transformation in healthcare, and blockchain-enabled system reform—all focused on redefining how technology can drive transparency, efficiency, and equity across the $4.5 trillion healthcare economy.

The first session we've announced—"AI and Institutional Resistance - CEOs Driving Change in Legacy Sectors"—brings together TIME CEO Jessica Sibley alongside our CEO, Tim Johnson. for a dynamic discussion on how top executives are embedding AI within large, traditional organizations. This dialogue goes beyond innovation—it highlights the leadership mindset and operational courage required to modernize industries that have historically resisted change.

Our second session, "First Ladies: Backing Women Who Build," will feature Cherie Blair CBE, KC, Founder of the Cherie Blair Foundation for Women. The panel will spotlight global leaders advancing women's entrepreneurship, leadership, and access to capital across industries—exploring how innovation, education, and technology can close gender gaps in business creation and economic opportunity. This aligns perfectly with Health In Tech's broader mission of expanding access and inclusion through technology-driven ecosystems.

Additional sessions focusing on other strategic themes will be announced in the months ahead.

![](ex99-1_001.jpg)

Together, these sessions elevate Health In Tech's visibility among insurers, investors, and policymakers, reinforcing our leadership in shaping conversations at the intersection of AI, healthcare, and financial inclusion. For investors, Davos represents a strategic inflection point—amplifying our institutional reach, strengthening our brand presence on the world stage, and showcasing how our technology and partnerships are modernizing the healthcare ecosystem here in the U.S.

As I've often said, legacy sectors like healthcare, finance, and insurance are where AI meets its toughest tests—and delivers its greatest rewards. By leading these discussions, Health In Tech is demonstrating that responsible, data-driven innovation can scale sustainably while earning trust from both partners and regulators.

With that, I'll turn the call over to our Chief Financial Officer, Julia Qian, to walk you through the financial results in more detail. Julia?

**Julia Qian – CFO**

Thanks, Dustin, and good afternoon, everyone. It's a pleasure to walk you through the financial results that underpin the strong operational achievements Tim just discussed.

Our **third quarter and first nine months of 2025** reflect continued execution across all business fronts — from expanding our sales distribution network to launching new platform features — while maintaining disciplined cost management and operational efficiency.

**Revenue Performance**

For the **third quarter**, total revenue reached **$8.5 million**, bringing **year-to-date revenue to $25.8 million**, which represents **132% of our full-year 2024 total**. This growth clearly demonstrates our accelerating momentum and the effectiveness of our strategic channel expansion through brokers, TPAs, and agencies, combined with strong customer acquisition activity.

**Profitability and Operating Leverage**

Beyond the top line, our **profitability metrics show significant operating leverage.**

● **Adjusted EBITDA** for the quarter was **$1.0 million**, up **49% year over year**.

● For the first nine months, **adjusted EBITDA reached $3.8 million**, or **167% of our full-year 2024 total.** 

This strong EBITDA performance demonstrates our ability to **scale efficiently while maintaining cost discipline.**

**Pre-tax income** for the quarter was **$0.6 million**, a **48% increase year over year.** For the first nine months, pre-tax income totaled **$2.1 million**, or **2.4 times our full-year 2024 level.** Importantly, pre-tax income represented **8.2% of revenue**, a **135-basis-point improvement year over year**, reflecting a consistent balance between **resource allocation for growth and bottom-line profitability.**

**Expense Management**

On the expense side, we continue to improve operating efficiency as we scale.

● **Total operating expenses** for the third quarter were **$4.7 million**, or **55% of revenue**, down from **68%** in the same period last year.

● For the first nine months, operating expenses represented **59% of revenue**, an **improvement of 12 percentage points** from **71%** a year ago.

![](ex99-1_001.jpg)

We continue to integrate **AI-driven internal solutions** to enhance process automation and reduce administrative burden.

Breaking this down further:

● **Sales and Marketing** expenses were **$1.0 million**, or **11.3% of revenue**, essentially flat year over year. Our **channel-partnership model** continues to drive revenue growth without the need for a large in-house sales force.

● **General and Administrative (G&A)** expenses were **$3.5 million**, consisting of **$1.3 million** in operating costs (14.9% of revenue) and **$2.2 million** in administrative costs (25.8% of revenue). The higher admin cost reflects expenses associated with being a **public company**, including **D&O insurance, board compensation, investor relations, and media outreach**.

● **Research and Development (R&D)** expenses declined to **2.8% of revenue**, from **16.1%** a year ago, as our tech resources have shifted from preliminary project phase to heavy development, deployment and feature enhancement phases.

**Cash Flow and Balance Sheet**

For the first nine months, we generated **$2.7 million of positive cash flow from operations.**

We invested **$2.4 million** in technology development and **$0.1 million** in capital markets activities, resulting in **net positive cash flow of $0.2 million.** We ended the quarter with a solid **$8.0 million in cash and cash equivalents.**

Our **collaboration with AlphaTON Capital** also provides additional capital leverage for the **HITChain** initiative. With AlphaTON's investment contribution, we expect to build this transformative blockchain-enabled platform with **minimal cash requirement on our side**, maximizing our capital efficiency.

As we enter the fourth quarter, we are navigating a period of **market uncertainty** driven by **rising healthcare costs and evolving regulatory developments.** Some employers have accelerated plan selections into late Q3, while others are deferring decisions into early 2026. As a result, we anticipate **Q4 revenue growth of approximately 50% year over year**—a solid outcome given these timing shifts.

As Tim noted, we began testing the Three-Year Rate Hold Program in October. This initiative strengthens our visibility into future revenue streams by extending client commitments over multi-year periods. Once fully launched in early 2026, it's expected to enhance retention, improve predictability in contract renewals, and contribute to more stable cash flows over time. We view this as a disciplined, capital-efficient way to expand our product offering while reinforcing the recurring nature of our revenue model.

In summary, the third quarter represented a **pivotal stage of technological advancement and product innovation**, the fourth quarter will be marketing and testing of new program and running year- end sales champion that builds tremendous momentum for 2026. We are laying the groundwork for an **AI-enabled, multi-program healthcare insurance marketplace** serving businesses of all sizes.

I'll now turn it back over to the operator for Q&A.

**Question-and-Answer Session**

**Operator**

Thank you. Seeing no more questions in the queue, let me turn the call back to Mr. Johnson for closing remarks.

**Tim Johnson– CEO**

Thank you, operator and thank you all. I appreciate everyone joining the call today, if anyone has any follow up questions, please do not hesitate to reach out to us. We appreciate your interest and look forward to keeping the dialogue open. Thanks everyone.

**Operator**

Thank you all again. This concludes the call. You may now disconnect.